← Back to Clinical Trials
Recruiting NCT05960604

NCT05960604 Pressure Recording Analytical Method Parameters and Their Relationship With Hypotension in Hypertensive Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05960604
Status Recruiting
Phase
Sponsor Recep Tayyip Erdogan University
Condition Cardiovascular Diseases
Study Type OBSERVATIONAL
Enrollment 660 participants
Start Date 2024-02-19
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Passive leg raising

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 660 participants in total. It began in 2024-02-19 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Perioperative anesthesiologists can benefit from easily obtainable hemodynamic variables detecting or quantifying the lack of an adequate compensatory capacity of the cardiovascular system in order to optimize patient management and improve patient outcomes. Parameters of the Pressure Recording Analytical Method (PRAM; Vygon, Padua, Italy) of the MostCare system, specifically cardiac cycle efficiency has been proposed as such variables. Yet, their value in anesthesia and especially in hypertensive patients is not studied. The goal of the PRAM-in-HYPO study is to prospectively evaluate the relationship between cardiac reserve and efficiency and cardiovascular risk factors in patients wo will undergo major surgical procedures using the state-of-the-art hemodynamic monitors. Also the investigators aim to build a predictive model to identify patients with decreased cardiac reserve due to hypertension and other cardiovascular risk factors, who are susceptible to post-induction hypotension. The investigators seek to include high-risk patients or patients presenting for major surgery, who are monitored with an advanced hemodynamic monitor to adequately evaluate the differences in cardiac reserve and cardiac efficiency.

Eligibility Criteria

Inclusion Criteria: * Age at least 18 years * Undergoing major surgery under general anesthesia * Expected surgery time \>2 h * Expected length of postoperative stay \>2 d * Invasive blood pressure (radial or femoral) and Mostcare monitoring * Indication for a passive leg raising test: risk of hypovolemia (preoperative fasting, bowel preparation, loss of appetite, limited access to water) or expected major surgery, expected blood loss, cardiovascular comorbidity (hypertension, diabetes mellitus, coronary artery disease, peripheral artery disease, hyperlipidemia, morbidity, active smoking). * Recruitment after booking for surgery with sufficient time to read, understand and question study patient information prior to attending for surgery. * Ability and willingness to provide informed consent Exclusion Criteria: * Refuse to consent to the study * Arterial wave form distortion * Cardiac arrhythmia * Inappropriate identification of the dicrotic notch for any reason * Planned intraoperative mean arterial blood pressure \< 65 mmHg * Hemodynamic instability defined as mean arterial blood pressure \< 65 mmHg * Preoperative requirement of inotrope/vasopressor infusion * Preoperatively receiving vasoactive drugs * Patients fitted with an intra-aortic balloon pump * Patients fitted with Extracorporeal Membrane Oxygenation * Critically ill patients requiring preoperative intensive care unit * Presence of intraabdominal hypertension * New York Heart Association Class 3-4 heart failure * Congestive heart failure with ejection fraction \< 35% * Glomerular filtration rate \< 30 ml/min/1.73 m2 * Ongoing renal replacement therapy

Contact & Investigator

Central Contact

Başar Erdivanlı, Assoc. Prof.

✉ basar.erdivanli@erdogan.edu.tr

📞 +90-505-7800730

Principal Investigator

Fevzi Toraman, Prof.

STUDY DIRECTOR

Acibadem University

Frequently Asked Questions

Who can join the NCT05960604 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05960604 currently recruiting?

Yes, NCT05960604 is actively recruiting participants. Contact the research team at basar.erdivanli@erdogan.edu.tr for enrollment information.

Where is the NCT05960604 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye), Erzurum, Turkey (Türkiye), Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye) and 1 additional location.

Who is sponsoring the NCT05960604 clinical trial?

NCT05960604 is sponsored by Recep Tayyip Erdogan University. The principal investigator is Fevzi Toraman, Prof. at Acibadem University. The trial plans to enroll 660 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology